Concepedia

D. M. Hamlin

DM

6

Publications

296

Citations

6

H-Index

1995

Active since

Affiliations

Eli Lilly (United States)(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

GlaxoSmithKline (United States)

Janssen (United States)

D. M. Hamlin is an author at Eli Lilly (United States) specializing in medicine, physiology, and human metabolism.

Top concepts

Publications per year

1995–2021

6

Publications

6

COMPARATIVE POLYCLONAL ANTITHYMOCYTE GLOBULIN AND ANTILYMPHOCYTE/ANTILYMPHOBLAST GLOBULIN ANTI-CD ANTIGEN ANALYSIS BY FLOW CYTOMETRY

James S. Bourdage, D. M. Hamlin · Transplantation · 1995 · 161 citations

A Performance Evaluation of Three Drug-Induced Liver Injury Biomarkers in the Rat: Alpha-Glutathione S-Transferase, Arginase 1, and 4-Hydroxyphenyl-Pyruvate Dioxygenase

Wendy J. Bailey, Dan Holder, Hima Patel et al. · Toxicological Sciences · 2012 · 45 citations

, , +25

Rat Urinary Osteopontin and Neutrophil Gelatinase-Associated Lipocalin Improve Certainty of Detecting Drug-Induced Kidney Injury

Jonathan A. Phillips, Daniel Holder, Daniela Ennulat et al. · Toxicological Sciences · 2016 · 42 citations · Full text

Evaluation of Renal Biomarkers, Including Symmetric Dimethylarginine, following Gentamicin-Induced Proximal Tubular Injury in the Rat

D. M. Hamlin, A. Eric Schultze, Michael J. Coyne et al. · Kidney360 · 2021 · 20 citations · Full text

Cisplatin nephrotoxicity in male beagle dogs: next-generation protein kidney safety biomarker tissue expression and related changes in urine

J. Eric McDuffie, Y. Chen, J. Y. et al. · Toxicology Research · 2016 · 16 citations · Full text

Rows per page

1–5 of 6